Ngm Biopharmaceuticals Stock Price, News & Analysis

NGM Biopharmaceuticals (NGM) presented new findings on NGM936, a bispecific T cell engager targeting ILT3 in acute myeloid leukemia (AML), at the ASH Annual Meeting. NGM936 showed potent T cell-dependent cytotoxicity against ILT3+ AML cells while minimizing cytokine release. With ILT3 specificity, it promises targeted treatment for monocytic AML, a subtype with poor prognosis, accounting for 25-30% of AML cases. NGM Bio plans to seek a partner for clinical development in hematologic oncology.

NGM Biopharmaceuticals presented preliminary data on NGM707 at the ESMO I-O Annual Congress, showing it was generally well tolerated up to 1800 mg with no maximum tolerated dose reached. The drug demonstrated linear pharmacokinetics at doses ≥200 mg and early anti-tumor activity in a Phase 1 trial involving 34 patients with various solid tumors as of November 23, 2022. Notably, there were partial responses in one patient and stable disease in six others, with some patients experiencing significant tumor size reductions, including a 70% decrease. Ongoing enrollment aims to expand effective treatment.

NGM Biopharmaceuticals (NASDAQ: NGM) announced that preliminary data from its Phase 1a study of NGM707, an ILT2/ILT4 dual antagonist antibody, will be presented at the ESMO I-O Annual Congress on December 8, 2022. The ongoing trial focuses on patients with advanced solid tumors expressing ILT2 and ILT4. NGM707 aims to reprogram suppressive cells in the tumor microenvironment to encourage anti-tumor immunity. The company plans to enroll approximately 220 patients in this study, which is part of its wider oncology portfolio.

NGM Biopharmaceuticals (NGM) announced the acceptance of an abstract for their bispecific T-cell engager program, NGM936, at the ASH Annual Meeting from December 10-13, 2022. The presentation will cover NGM936's potential in treating ILT3-positive acute myeloid leukemia and multiple myeloma. Dr. Fabiana Perna from Indiana University will present research supporting NGM936's efficacy. The company emphasizes its focus on developing transformative therapies and currently has seven clinical programs, with four in advanced phases.

NGM Biopharmaceuticals reported disappointing results from the Phase 2 CATALINA trial of NGM621 for geographic atrophy, failing to meet its primary endpoint. Updated findings from Phase 1 trials of NGM120 for cancer were shared at prestigious conferences. Financially, the company posted a net loss of $47.3 million for Q3 2022, up from a $28.9 million loss in Q3 2021. Revenue from collaborations decreased significantly, and R&D expenses rose to $46.1 million, driven by ongoing clinical trials. NGM Bio holds $300.2 million in cash, projected to fund operations until Q4 2024.

NGM Biopharmaceuticals (NGM) recently shared findings from the post-hoc analyses of its Phase 2 CATALINA trial for NGM621, aimed at treating geographic atrophy (GA) due to age-related macular degeneration (AMD). The trial's primary endpoint was the change in GA lesion area over 52 weeks. Although initial results showed a 6.3% and 6.5% reduction in lesion area for different dosing schedules, these did not reach statistical significance. However, post-hoc evaluations revealed a promising 21.9% and 16.8% reduction in specific patient subgroups, indicating potential for further exploration.

NGM Biopharmaceuticals announced results from its CATALINA Phase 2 trial of NGM621 for geographic atrophy, revealing that the trial did not meet its primary endpoint of statistically significant reduction in GA lesion area over 52 weeks compared to sham treatment. NGM621 exhibited a favorable safety profile, showing no significant increase in choroidal neovascularization (CNV) and no treatment-related serious adverse events. Further analyses are set to be presented at The Retina Society Annual Scientific Meeting in November.

NGM Biopharmaceuticals, Inc. (NGM) will host a conference call on October 17, 2022, at 8:00 a.m. ET to discuss topline efficacy and safety results from the CATALINA Phase 2 trial of NGM621, targeting geographic atrophy due to age-related macular degeneration. The trial's results are crucial for understanding the potential therapeutic impact of NGM621 on this condition. Investors can access the live webcast and slides on the company's website, which will be archived for 30 days. NGM continues to develop seven clinical programs across various therapeutic areas.

NGM Biopharmaceuticals (NGM) announced promising results from its Phase 1b trial of NGM120, an antibody targeting GFRAL, for metastatic pancreatic cancer. The treatment was well tolerated with no dose-limiting toxicities. Among six evaluable patients, there was a 100% disease control rate, and the 12-month survival rate was 83.3%. Notably, three patients achieved partial responses lasting over 32 weeks, with one ongoing at 90 weeks. Further studies, including a Phase 2 trial, are planned to explore NGM120's efficacy in combination with gemcitabine and Nab-paclitaxel.